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Abstract
Background: The number of patients with non-HIV Pneumocystis pneumonia (PCP) is increasing with widespread
immunosuppressive treatment. We investigated the clinical characteristics of non-HIV PCP and its association with
microbiological genotypes.
Methods: Between January 2005 and March 2010, all patients in 2 university hospitals who had been diagnosed
with PCP by PCR were enrolled in this study. Retrospective chart review of patients, microbiological genotypes, and
association with 30-day mortality were examined.
Results: Of the 82 adult patients investigated, 50 patients (61%) had inflammatory diseases, 17 (21%) had solid
malignancies, 12 (15%) had hematological malignancies, and 6 (7%) had received transplantations. All patients
received immunosuppressive agents or antitumor chemotherapeutic drugs. Plasma (1®3) b-D-glucan levels were
elevated in 80% of patients, and were significantly reduced after treatment in both survivors and non-survivors.
However, b-D-glucan increased in 18% of survivors and was normal in only 33% after treatment. Concomitant
invasive pulmonary aspergillosis was detected in 5 patients. Fifty-six respiratory samples were stored for
genotyping. A dihydropteroate synthase mutation associated with trimethoprim-sulfamethoxazole resistance was
found in only 1 of the 53 patients. The most prevalent genotype of mitochondrial large-subunit rRNA was
genotype 1, followed by genotype 4. The most prevalent genotype of internal transcribed spacers of the nuclear
rRNA operon was Eb, followed by Eg and Bi. Thirty-day mortality was 24%, in which logistic regression analysis
revealed association with serum albumin and mechanical ventilation, but no association with genotypes.
Conclusions: In non-HIV PCP, poorer general and respiratory conditions at diagnosis were independent predictors
of mortality. b-D-glucan may not be useful for monitoring the response to treatment, and genotypes were not
associated with mortality.
Background
Pneumocystis jirovecii pneumonia (PCP) is widely known
as an opportunistic infection in human immunodefi-
ciency virus (HIV)-infected patients. The introduction of
chemoprophylaxis and highly active antiretroviral ther-
apy has reduced the incidence of HIV PCP in recent
years [1,2]. In contrast, PCP in non-HIV immunocom-
promised patients is increasing as the number of
patients receiving transplantation, immunosuppressive
therapy, and antitumor chemotherapeutic agents con-
tinues to grow [1].
For years, the standard method for laboratory diagno-
sis of PCP was the visualization of P. jirovecii by micro-
scopy in bronchoalveolar lavage (BAL) fluid or induced
sputum. It is known that non-HIV patients often
develop PCP with a lower parasite burden than HIV
patients [3], which may result in a false negative micro-
scopic determination [4]. Although immunofluorescent
antibody stain has improved the sensitivity compared to
Gomori methenamine silver or Giemsa stains [5], a
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recently been employed [6,7]. However, being PCR-posi-
tive does not necessarily indicate a diagnosis of PCP.
Pneumocystis colonization, defined as detection of the
organism or its DNA without signs or symptoms of
pneumonia, has been reported irrespective of immuno-
suppressive conditions [8]. Furthermore, PCR-positive
patients with pulmonary infiltrates diagnosed as a pneu-
monia other than PCP were also considered to have
colonization of P. jirovecii [4,9]. Without microscopy-
positive patients, differentiation between PCP and colo-
nization can only be done by clinical diagnosis. For
adjunctive diagnosis, (1®3) b-D-glucan tests have also
been used [10-12]. Because most of the studies on non-
HIV PCP have been based on microscopic diagnosis, its
clinical characteristics, including the b-D glucan test in
PCR-diagnosed non-HIV PCP patients, are still not well
described.
Strain analysis of P. jirovecii had been conducted by
molecular genotyping based on nucleotide sequence var-
iations because of the inability to culture. Studies mainly
on HIV PCP have targeted the mitochondrial large-sub-
unit rRNA (mt LSU rRNA) and internal transcribed
spacer (ITS) regions of the nuclear rRNA operon, and
the dihydropteroate synthase (DHPS) gene [13]. Mt LSU
rRNA and ITS have been used to analyze the cluster of
PCP, the route of transmission, and association of sever-
ity [13,14]. The DHPS mutation is thought to be asso-
ciated with failure of treatment and prophylaxis [15,16].
However, molecular epidemiology and the clinical rela-
tionship with non-HIV PCP have been described in only
small-scale studies.
In this study, we describe the clinical characteristics of
non-HIV PCP based on PCR diagnosis. This includes
the underlying conditions, laboratory findings such as b-
D glucan tests, complications, and the association of
prognostic factors. We also evaluate the clinical signifi-
cance of microbiological genotypes.
Methods
Study site and population
We retrospectively reviewed all consecutive non-HIV
patients tested by pneumocystis PCR analysis between
January 2005 and March 2010 at 2 tertiary care univer-
sity hospitals, Kyoto University Hospital and Nagoya
University Hospital, in Japan. After reviewing the medi-
cal records for all patients tested, diagnoses of PCP were
made if the patients met all of the following criteria:
new ground glass opacities in chest computed tomogra-
phy, positive PCR targeting of mt LSU rRNA, and clini-
cal suspicion of PCP by an attending physician defined
as presumptive treatment for PCP. Presumptive treat-
ment occurred when PCR results were pending and
continued until resolution or death. Only patients with
the first episode of PCP were included. If multiple sam-
ples were taken for a patient, the samples were taken in
the following order: BAL fluid, sputum, and oral wash.
The Ethics Committee of Kyoto University Graduate
School and Faculty of Medicine (E-356) and the Institu-
tional Review Board of Nagoya University Graduate
School of Medicine (641) approved this study and
waived the need for obtaining informed consent from
each patient.
Data collection
Clinical information acquired by medical chart review
included underlying diseases, immunosuppressive thera-
pies during the previous month, PCP prophylaxis, clini-
cal symptoms, laboratory values, Sequential Organ
Failure Assessment (SOFA) score [17], anti-PCP treat-
ment, complications, invasive fungal infections, and
30-day mortality. The daily dosage of corticosteroids
was expressed as the prednisolone equivalent (1 mg of
prednisolone equals 0.8 mg of methylprednisolone
equals 1 mg of prednisone). Hypoxemia was defined as
arterial PaO2 < 70 mm Hg in room air or a requirement
for supplemental oxygen. Invasive fungal infection was
diagnosed according to the European Organization for
Research and Treatment of Cancer criteria [18].
b-D-glucan assay
Plasma b-D-glucan was measured with the b-glucan test
WAKO (Wako Pure Chemical Industries; Tokyo, Japan).
Plasma samples were collected before and after PCP
treatment. The assay was performed as a clinical routine
at our institution on the same day when the plasma was
obtained.
PCR detection and genotyping
DNA was extracted using the QIAamp DNA mini kit
(Qiagen; Hilden, Germany). Molecular detection of P.
jirovecii was carried out by single round PCR amplifica-
tion of mt LSU rRNA [19].
DHPS genotypes were determined by nested PCR and
RFLP analysis [20], based on codon 55/57 mutations:
wild type (Thr/Pro), single mutant (Ala/Pro or Thr/Ser),
a n dd o u b l em u t a n t( A l a / S e r ) .M tL S Ur R N Ag e n o t y p e s
were determined by direct sequencing at nucleotides 85
and 248: genotype 1 (C/C), 2 (A/C), 3 (T/C), 4 (C/T),
and 5 (C/T). When mixed genotypes were suspected,
amplification products were cloned and then 5 clones
were randomly selected and sequenced. ITS regions
were amplified by nested PCR [21], and the 5 clones
were analyzed using scores described elsewhere [22-25].
If multiple haplotypes (combinations of ITS1 and ITS2
types) were detected from 1 sample, mixed-type were
considered only when both haplotypes were detected in
at least 1 single-type sample.
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come, we compared each genotype with hypoxemia,
SOFA score, mechanical ventilation, and 30-day
mortality.
Statistical analysis
Categorical variables were compared using Fisher’s exact
test. Continuous variables were compared using the
Mann-Whitney U test. b-D-glucan values under the
commercial upper limit of the normal value of 11 pg/
mL were considered to be 1.1 pg/mL when comparing
the values before and after treatment. To determine the
association of independent variables with 30-day mortal-
ity, a stepwise logistic regression analysis was performed.
Variables with a P-value of less than 0.10 on univariate
analyses were included in the multiple regression model
with step forward analysis. P < 0.05 was considered sta-
tistically significant. We performed our statistical ana-
lyses using R version 2.9.2 (R foundation for Statistical
Computing; http://www.r-project.org).
Results
As detailed in Figure 1, 260 samples from 195 patients
were tested by PCR during the 5-year observation per-
iod, and 82 patients fulfilled the inclusion criteria.
Among 78 patients who did not receive presumptive
treatment, 2 patients received treatment after PCR
results turned out to be positive. The final diagnoses in
33 patients with no presumptive treatment and positive
PCR results were infection other than PCP (bacterial
pneumonia, n = 5; aspergillosis, n = 3; atypical pneumo-
nia, n = 1; tuberculosis, n = 1; viral pneumonia, n = 1),
interstitial pneumonia associated with collagen diseases
(n = 8), drug-induced pneumonia (n = 5), miscellaneous
(n = 4), and unknown etiology (n = 5).
Of 82 PCP patients, 64 patients (39 males) were from
Kyoto University Hospital and 18 (12 males) were from
Nagoya University Hospital. The median age was
64 years (range, 19-82 years). Respiratory samples that
were obtained for PCR were sputum in 41 patients, BAL
fluid in 35, and oral wash in 6. Sputum or oral wash
were simultaneously obtained in 9 patients who under-
went bronchoscopy, which were all PCR-positive. Some
of the samples underwent microscopic analysis using
the Gomori methenamine silver stain. Eight of 33 (24%)
samples of BAL fluid and 2 of 31 (6%) of sputum were
microscopically positive.
Clinical Characteristics
Underlying diseases and conditions of patients are listed
in Table 1. All patients had received some kind of
immunosuppressive therapy; 74 patients (90%) received
corticosteroids or immunosuppressive agents and the
other 8 patients received antitumor chemotherapy alone.
195 patients (260 samples) were tested by PCR
169 patients with ground glass opacities
26 patients were excluded
20 patients had no ground glass opacities
6 patients were infected with HIV
91 patients received 
presumptive treatment
78 patients did not receive 
presumptive treatment
82 patients with 
positive PCR results
54 patients with 
negative PCR results
82 patients were 
included in the study
33 patients with 
positive PCR results
Figure 1 Inclusion of patients.P C R :p o l y m e r a s ec h a i nr e a c t i o n ;
HIV: Human Immunodeficiency Virus.
Table 1 Patient demographics at diagnosis of
pneumocystis pneumonia in 82 patients
Characteristics No. (%)
Age, years (range) 64 (19-82)
Male sex 51 (62%)
Underlying disease
Inflammatory disease 50 (61%)
Rheumatoid arthritis 17 (21%)
Systemic lupus erythematosus 10 (12%)
Vasculitis 7 (9%)
Inflammatory myopathy 4 (5%)
Pemphigus or pemphigoid 3 (4%)
Miscellaneous 11 (13%)
Solid malignancy 17 (21%)
Lung cancer 9 (11%)
Other tumors 8 (10%)
Hematological malignancy 12 (15%)
Malignant lymphoma 6 (7%)
Myelodysplastic syndrome 3 (4%)
Miscellaneous 3 (4%)
Organ transplantation 6 (7%)
Kidney 3 (4%)
Liver 2 (2%)
Bone marrow 1 (1%)
Fulminant hepatitis 2 (2%)
Pulmonary disease other than lung cancer 18 (22%)
Interstitial pneumonia 9 (11%)
Chronic obstructive pulmonary disease 4 (5%)
Miscellaneous 5 (6%)
Current or ex-smoker 28 (34%)
Some patients had 2 or more underlying diseases or conditions.
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65 patients (79%), with a median dose of prednisone of
13 mg/day. Twenty-four patients (29%) had received
corticosteroids less than 10 mg/day and 7 (9%) patients
for a period of less than 1 month. Forty-one (50%)
patients had received immunosuppressive agents other
than corticosteroids, with methotrexate as the most
commonly used agent (20 patients, 24%), followed by
cyclosporin (10 patients, 12%), tacrolimus (8 patients,
10%), and the antitumor necrosis factor-a drugs,
infliximab and etanercept (6 patients, 7%). Twenty-two
patients (27%) had received antitumor chemotherapy.
Prophylactic therapy was used in 3 patients (4%). Two
patients had received TMP-SMX, at a dose of 1 single-
strength tablet once daily for 5 months and 3 inconse-
cutive days weekly for 2 weeks, respectively. Another
patient had received aerosolized pentamidine at a dose
of 300 mg once monthly for 2 months. No patient had a
neutrophil count under 500/mm
3. Lactate dehydrogen-
a s e( L D H )w a sa b o v et h eu p p e rl i m i to ft h en o r m a l
Table 2 Clinical characteristics
All patients Survivors Non-survivors
Characteristics (n = 82) (n = 62) (n = 20) P value
Corticosteroids 65 (79%) 48 (77%) 17 (85%) 0.55
Daily dose, mg 13 (10-23) 13 (10-25) 15 (11-20) 0.39
Less than 10 mg/day 24 (29%) 20 (32%) 4 (20%) 0.40
Total duration, days 152 (66-943) 153 (67-889) 147 (38-2346) 0.95
Less than 1 month 7 (9%) 4 (6%) 3 (15%) 0.35
Immunosuppressive agents 41 (50%) 35 (56%) 6 (30%) 0.07
Antitumor chemotherapy 22 (27%) 14 (23%) 8 (40%) 0.15
PCP Prophylaxis 3 (4%) 1 (2%) 2 (10%) 0.15
Lower respiratory symptoms 74 (90%) 55 (89%) 19 (95%) 0.67
Fever 56 (68%) 42 (68%) 14 (70%) 1.00
Hypoxemia 57 (70%) 39 (63%) 18 (90%) 0.03
PaO2/FiO2 ratio (n = 50) 277 (168-341) 304 (186-356) 183 (108-318) 0.07
SOFA score 2 (1-4) 2 (1-3) 3 (1-5) 0.11
Laboratory findings
Neutrophils,/mm
3 6750 (5000-9525) 6250 (4975-8700) 8100 (5475-15425) 0.06
Lymphocytes,/mm
3 545 (400-1100) 750 (475-1225) 500 (200-675) 0.03
Thrombocytes,/mm
3 15.9 (11.5-24.7) 16.2 (12.2-25.3) 14.3 (7.3-24.7) 0.20
C-reactive protein, mg/dL 6.4 (2.5-10.7) 5.6 (2.5-9.6) 8.5 (2.1-13.6) 0.18
Albumin, mg/dL 2.8 (2.4-3.2) 2.9 (2.5-3.3) 2.3 (2.2-2.9) 0.007
Creatinine, mg/dL 0.9 (0.6-1.3) 0.9 (0.6-1.2) 0.9 (0.6-1.6) 0.53
Blood urea nitrogen, mg/dL 21 (16-31) 20 (15-27) 30 (16-63) 0.25
Total bilirubin, mg/dL 0.6 (0.4-0.9) 0.6 (0.4-0.8) 0.7 (0.5-0.9) 0.43
Lactate dehydrogenase, IU/L 394 (303-501) 368 (291-485) 456 (366-662) 0.007
LDH > upper limit of normal value 76 (93%) 56 (90%) 20 (100%) 0.33
b-D-glucan (n = 81), pg/mL 39.7 (14.5-207.5) 36.3 (15.0-204.7) 53.6 (11.3-353.7) 0.50
b-D-glucan (n = 81) >11 pg/mL 65 (80%) 49 (79%) 15 (79%) 1.00
Initial Treatment
TMP-SMX 77 (94%) 58 (94%) 19 (95%) 1.00
Drug change 19 (25%) 13 (22%) 6 (32%) 0.54
Pentamidine 5 (6%) 4 (6%) 1 (5%) 1.00
Drug change 1 (20%) 1 (25%) 0 (0%) 1.00
Adjunctive steroid therapy 60 (73%) 44 (71%) 16 (80%) 0.57
Anti-cytomegalovirus therapy 23 (28%) 15 (24%) 8 (40%) 0.25
Mechanical ventilation 22 (27%) 9 (15%) 13 (65%) <0.001
Pneumothorax 4 (5%) 1 (2%) 3 (15%) 0.04
Invasive pulmonary aspergillosis 5 (6%) 1 (2%) 4 (20%) 0.01
Data are presented as the No. (%) or median (interquartile range). Steroid dosages are expressed as corresponding amounts of prednisolone. Categorical
variables were compared using Fisher’s exact test, and continuous variables were compared using the Mann-Whitney U test.
PCP: pneumocystis pneumonia; SOFA: Sequential Organ Failure Assessment; LDH: lactate dehydrogenase; TMP-SMX: trimethoprim-sulfamethoxazole.
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Nagoya University) in 76 patients (93%). b-D-glucan was
elevated in 65 (80%) of 81 patients. Probable invasive
pulmonary aspergillosis was concomitant with 5 PCP
patients who had inflammatory diseases. In addition to
ground glass opacities, 2 patients had nodules without a
halo sign, 2 had consolidation, and 1 had an air-crescent
sign. All 5 patients were positive by enzyme-linked
immunosorbent assay for the detection of Aspergillus
galactomannan at a threshold of 1.0. One patient was
also positive with culture of Aspergillus fumigatus.
Three patients developed aspergillosis after PCP diagno-
sis, 1 simultaneously, and 1 before. Four patients had
elevated levels of b-D-glucan before and after PCP treat-
ment. As aspergillosis can influence b-D-glucan levels,
we excluded those patients with aspergillosis from the
analysis of b-D-glucan monitoring. No other invasive
fungal disease or mycobacterial infection was identified.
Levels of b-D-glucan after treatment were significantly
reduced in both groups of 56 survivors and 7 non-survi-
vors (Figure 2). There were 10 survivors (18%) and 1
non-survivor (14%) whose b-D-glucan increased after
treatment. Normalization occurred in only 33% of survi-
vors (15 of 46) and in 14% of non-survivors (1 of 7).
The crude 30-day mortality was 24% (20 deaths).
Table 2 shows the factors that were significantly asso-
ciated with mortality in univariate analysis, such as
hypoxemia (p = 0.03), low lymphocytes (p = 0.03), low
serum albumin (p = 0.007), high LDH (p = 0.007),
mechanical ventilation (odds ratio [OR], 10.9; 95% con-
fidence interval [CI], 3.4 to 34.9), pneumothorax (OR,
10.8; CI, 1.1 to 110.2), and invasive pulmonary asper-
gillosis (OR 15.3; CI, 1.6 to 146.1). Multivariate
analysis revealed that low serum albumin and mechan-
ical ventilation were independent predictors of mortal-
i t y( T a b l e3 ) .
Genotyping
Respiratory samples from 56 (68%) patients were sub-
jected to genotyping (Table 4). The other 26 samples
taken before January 2008 at Kyoto University and
September 2008 at Nagoya University were not stored.
The mt LSU rRNA genotype analyses were successful in
all of the 56 patients. Genotype 1 was most common
(30%), followed by genotype 4 (27%), genotype 2 (18%),
genotype 3 (13%), genotype 5 (2%), and mixed genotype
(11%). The DHPS gene was amplified in 53 patients
(95%). Of the patients without prophylaxis, only 1 patient
had the double mutation and all the others were wild-
type. The ITS gene was amplified in 31 patients (55%).
We identified 9 unique ITS haplotypes from a single-
type sample. Genotypes Ci, Ea, Ef, Ei, Hg, and Jf were
detected only in mixed-type samples, each from
1 patient. The most prevalent ITS types were Eb
(9 patients, 29%), followed by Eg (6 patients, 19%), and
then Bi (5 patients, 16%). Mixed-types were detected in
5 patients (16%). The ITS genotype and epidemiological
distribution showed no cluster outbreak in this study
period. None of the genotypes of 3 genetic loci were
associated with hypoxemia, SOFA score, mechanical
ventilation, or mortality in univariate analysis. The
DHPS gene was excluded from analysis because only
1 patient had the mutant genotype.
Discussion
PCP is diagnosed by identifying P. jiroveci in respiratory
s p e c i m e n s ,b u ti ti so f t e nd i f f i c u l tt oo b t a i nB A Ls a m -
ples in non-HIV patients with severe and rapidly pro-
gressive disease [3,26]. Highly sensitive PCR allowed us
to detect P. jirovecii in samples with negative direct
examination tests and in non-invasive samples, such as
induced sputum [4] or oral wash [27]. Although PCR
for P. jiroveci can be positive in asymptomatic colonized
patients, PCP therapy is recommended in patients with
clinical suspicion of PCP and positive PCR results [7].
According to these backgrounds, our diagnostic criteria
included presumptive treatment due to strong suspicion
by a clinician for PCP, in addition to the PCR and ima-
ging studies. We excluded 2 patients for whom treat-
ment was initiated after the PCR result. Because it
usually takes 3 to 10 days to get PCR results in our
practice, a delay in treatment would have some effect
over outcomes. PCR-positive patients without treatment
had clinical diagnoses other than PCP. PCR-negative
patients irrespective of receipt of treatment were also
excluded, because PCR in non-HIV patients has a quite
high negative predictive value [4].
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Figure 2 Plasma b-D-glucan levels before and after treatment.
Values after treatment were measured at day 21 in survivors and at
day 17 in non-survivors (median value). Values after treatment were
significantly reduced in both groups by the Mann-Whitney U test.
Values under the commercial cutoff value of 11 pg/mL were
considered to be 1.1 pg/mL.
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lular immunity and the use of immunosuppressive
agents, especially corticosteroids. Similar to previous
reports [28,29], even with a low dose or short duration
of corticosteroids, our patients developed PCP. In addi-
tion to corticosteroids, the introduction of high-intensity
immunosuppressive regimens such as anti-tumor necro-
sis factor-a drugs has increased in inflammatory dis-
eases. Post-marketing surveillance of anti-tumor
necrosis factor-a drugs revealed a much higher inci-
dence of PCP in Japan than in the US [30]. Six PCP
patients (7.3%) in this study received anti-tumor necro-
sis factor-a drugs. Reported attack rates of PCP in non-
HIV patients not receiving prophylaxis are highest in
hematological malignancies and transplantation [28,31].
In our study, almost two-thirds of PCP patients had
inflammatory diseases and fewer patients had hematolo-
gical malignancies or transplantation. This may be
because PCP prophylaxis is common in hematological
malignancies or transplantation, but not in inflammatory
diseases, and the number of patients with inflammatory
diseases in the general population is larger.
Elevated serum LDH levels have been noted in
patients with PCP [11] but were not specific. b-D-glucan
was reported to be elevated in 96% of 111 HIV patients
with microscopic diagnosis of PCP [10] and 78% of 18
non-HIV patients with a PCR-based diagnosis [32]. The
latter value is almost the same as our result (80%).
Some reports have found high b-D-glucan to be a pre-
dictor of death [32,33], while others have not [34,35].
The b-D-glucan value did not differ between survivors
and non-survivors in our study (Table 2). In a study of
21 non-HIV PCP patients of whom 2 died within 30
days, it was reported that b-D-glucan a median of 3
days after treatment had significantly decreased [35]. In
our study, b-D-glucan in survivors and non-survivors
was separately analyzed, and in both groups it was sig-
nificantly reduced after treatment. However, normaliza-
tion occurred only in 33% of survivors, and in some
patients from both groups, b-D-glucan increased after
treatment. In a report of 42 HIV PCP patients, normali-
zation after 3 weeks of successful treatment occurred in
only 17% of patients, and elevated levels were found in
21% of patients [10]. These results suggest that a
decrease of b-D-glucan simply corresponds with treat-
ment, but does not predict treatment response. Since b-
D-glucan is a cell wall component of P. jirovecii,t h e
level of b-D-glucan may reflect the organism burden
directly, not the severity of PCP. Limper et al. demon-
strated that mortality was not associated with organism
burden, but rather the number of neutrophils in the
lower respiratory tract [3]. When b-D-glucan increases
compared to the level before treatment, it may not indi-
cate deterioration of PCP.
Non-HIV immunocompromised patients often develop
invasive aspergillosis [36]. We found 5 patients who
developed probable aspergillosis. Although Aspergillus
has not been generally recognized as a co-pathogen of
P. jirovecii, it is possible that it is because both PCP and
aspergillosis develop with the use of immunosuppressive
agents [28,29,36]. Aspergillosis was found to be a signifi-
cant predictor of death in univariate analysis and almost
reached significance in multivariate analysis. Aspergillo-
sis should be considered when there is a poor treatment
response to PCP.
Twenty-four percent of our patients died, which is
similar to the reported mortality rate of 19 to 40%
[1,29,37]. We found that albumin and mechanical
Table 3 Clinical features associated with 30-day mortality in multivariate logistic regression analysis
Variable Odds ratio 95% C.I. P value
Immunosuppressive agents other than corticosteroids 0.31 0.07-1.41 0.13
Lymphocyte, per 100/mm
3 1.06 0.97-1.16 0.19
Albumin, per 0.1 mg/dL 0.85 0.73-0.99 0.03
Lactate dehydrogenase, per 100 IU/L 1.65 1.00-2.73 0.05
Mechanical ventilation 5.16 1.25-21.32 0.02
Invasive pulmonary aspergillosis 20.07 0.94-426.88 0.05
Table 4 Genotypes of Pneumocystis jirovecii in 56 patients
Genetic locus Total numbers tested Genotype
mt LSU rRNA 56 1 2 3 4 5 Mixed
17 (30) 10 (18) 7 (13) 15 (27) 1 (2) 6 (11)
ITS 31 Eb Eg Bi Ai, Ce, “H"r, Ir, Iu3,U 1e Mixed
9 (29) 6 (19) 5 (16) 1 (3) 5 (16)
Data are presented as No. (%). mt LSU r rRNA, mitochondrial large subunit; based on nucleotide 85/248, genotypes 1, C/C; 2, A/C; 3, T/C; 4, C/T; 5, A/T. ITS,
internal transcribed spacer. If multiple haplotypes (combinations of ITS1 and ITS2 types) were detected from 1 sample, mixed-type were considered only when
both haplotypes were detected in at least 1 single-type sample.
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Page 6 of 9ventilation were independent predictors. These factors
have been reported previously [29,37].
T h ee p i d e m i o l o g yo fP C Pi nl a r g en u m b e r so fn o n -
HIV patients separate to that of HIV patients has never
been reported. From a previous small Japanese study, 2
of 8 non-HIV patients had the DHPS mutation [38].
Our patients had a very low rate of DHPS mutations,
which cannot be generalized for non-HIV patients,
because mutant rates in HIV patients vary widely (3% to
69%) [16]. In addition, the prophylactic use of TMP-
SMX may be associated with the emergence of DHPS
mutant strains in HIV patients [39]. One possible expla-
nation of the low rate of DHPS mutants in our patients
is the rarity of prophylaxis.
There is little information about the clinical back-
ground of the mt LSU rRNA genotypes. The only study
describing the clinical relationships in 53 HIV and 7
non-HIV patients found no association [40]. We also
found no association in our patients. The largest study
that has investigated the genotypes of non-HIV PCP
included 17 patients from 3 PCP clusters in Sweden
[41]. Genotypes 1, 2, 3, and mixed-types were found in
5, 2, 3, and 7 patients, respectively. Other studies for
HIV PCP, non-HIV PCP, and non-HIV patients without
pneumonia found that genotypes 1 or 2 were the most
prevalent, and genotype 4 was the least prevalent
[20,40,42-45]. Genotype 1 was the most prevalent in our
study, which is consistent with those reports. However,
it is inconsistent with regard to genotype 4, which was
the second prevalent type in this study.
The clinical correlation with the ITS genotypes has been
conflicting [14,46]. We did not find a correlation. Some
studies have focused on the epidemiology of the ITS geno-
type in non-HIV PCP [40,47], but the number of patients
was less than 10. We investigated 31 patients and found
Eb, Eg, and Bi from multiple patients as a single haplotype.
Mixed infections were detected in 16%. Genotypes Eb, Eg,
Bi, and Ne are reported to be common in HIV PCP, and
mixed infections are reported in 5-79% [20,22-24,40,48].
Those previous studies overestimated the mixed infec-
tions, because many of the less common haplotypes
resulted from in vitro recombinations of globally common
ITS haplotypes present in the same sample [21].
Our study is retrospective, and it has several limita-
tions. One limitation is the heterogeneity of the respira-
tory sample and underlying clinical conditions. More
than half of the samples obtained for PCR were not
BAL fluid, and not all of the samples underwent micro-
scopic analysis. Of the PCR-diagnosed PCP, microscopic
examinations were positive only in 24% of BAL fluid
and in 6% of sputum. One possible reason for the low
positive rate is that Gomori methenamine silver stain
has less sensitivity than an immunofluorescent antibody
stain [5]. The underlying clinical conditions and stage of
disease might have varied, which could be uncontrolled
confounders of the cause of death. Another limitation is
that our study may still lack the statistical power to
determine a clinical relationship between genotypes and
outcome, although it is the largest to date on genotypes
of non-HIV PCP.
Conclusions
This is the largest study to date that describes the clini-
cal characteristics of non-HIV PCP based on PCR diag-
nosis. We found that inflammatory disease was the most
common underlying condition, and all of the patients
received immunosuppressive agents or chemotherapeu-
tic agents. b-D-glucan may not be useful for monitoring
the response to treatment. Predictors of death were
similar to previous reports, except that invasive pulmon-
ary aspergillosis was a predictor of death in univariate
analysis. During treatment, invasive pulmonary aspergil-
losis should be noted carefully. Microbiological geno-
types of non-HIV PCP were also described in the largest
population, in which there were few DHPS mutation
and no relationship with the clinical characteristics. The
prevalence of ITS and mt LSU rRNA genotypes in non-
HIV patients did not seem to be significantly different
when compared to reports for HIV patients. Further
investigation is needed to evaluate microbiological geno-
types from a clinical point of view.
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